Migraine Minute News Update

A study found that anti-CGRP monoclonal antibodies not only reduced absenteeism & presenteeism in Spain, they were found to be cost-effective too.

Read more: http://bit.ly/3S1KS5Y

Image courtesy: DOI 10.1186/s10194-024-01727-0

A new study looks at the efficacy and safety of two gepant medications. Molly O'Brien will share the study findings in this Migraine Minute News update. 

Read the study: bit.ly/4cwJQar

Image courtesy: Sage Journals. Cephalalgia doi:10.1177/03331024241235156

Light sensitivity and poor sleep quality in people with migraine, could the two be related? In a study published in the Journal of Headache and Pain, researchers looked at the impact photophobia may have on sleep quality in people with migraine. Molly O’Brien breaks it down in this Migraine Minute News Update.

Learn more: bit.ly/4cIJMUD

Caffeine habit? A new study looks at the link between episodic migraine and regular caffeine intake. Molly O’Brien will fill you in, in this latest Migraine Minute News Update.

Learn more about the study at bit.ly/4bzLyXu

The US FDA clears another wearable drug-free migraine treatment device. In this Migraine Minute News Update, Molly O’Brien will tell you all about a new TENS device available for people with episodic migraine.

Read more: https://bit.ly/4aEZFe9

Many people with chronic migraine worry that their monthly preventive medication won’t work as well at the end of the month as it did at the beginning. New research shows that two injectable CGRP monoclonal antibodies do not wear off at the end of the month.

Molly O’Brien has the details in this #MigraineMinute News Update.

Read more: bit.ly/3w95WQn

A study in the Lancet found one oral gepant to be safe and effective in people with episodic migraine who have failed two to four classes of preventive treatments. Molly O’Brien explains in this Migraine Minute News Update. Read the study here: https://bit.ly/3w3ZM45

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1

*The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25, 14 (2024). https://doi.org/10.1186/s10194-024-01721-6. The graphical abstract has been slightly modified.

 Researchers at the University of California Los Angeles found changes in blood flow in the retina might explain why some people have visual migraine symptoms. Molly O'Brien has the details in this Migraine Minute News update. 

Learn more: https://bit.ly/3xou7uw , https://bit.ly/4aErYZN

AMD is thrilled to share what we’ve learned so far from our HEADS Registry! Molly O'Brien goes over the exclusive new data in this Migraine Minute News Update. The HEADS Registry serves as a crucial resource for researchers and clinicians. It’s not too late to share your experience, by doing so, you can help pave the way for more effective therapies, enhanced and personalized patient care, and improved quality of life. Learn more at migrainedisorders.org/heads-registry/